by AnTolRx | Nov 29, 2016 | Articles
ASweetLife – Nanoparticles May Be Used to Treat Type 1 Diabetes “A couple of weeks ago I sat down with Dr. Francisco Quintana, who runs a lab at Brigham and Women’s Hospital in Boston focused on finding new treatments for autoimmune diseases. In... by AnTolRx | Sep 8, 2016 | Press Release
CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and JDRF, the leading global organization funding type 1 diabetes (T1D) research. The funding... by AnTolRx | Aug 31, 2016 | Publication
Yeste, A. et al. Sci Signal 9, ra61(2016) by AnTolRx | Aug 31, 2016 | Publication
Mascanfroni, I. D. et al. Nat Immunol 14, 1054–1063 (2013). by AnTolRx | Aug 31, 2016 | Publication
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L. & Quintana, F. J. Proc Natl Acad Sci USA 109, 11270–11275 (2012).